ADCs Pipeline Update: Daiichi Sankyo Initiates Clinical Trial

Daiichi Sankyo

On October 31, 2019, Daiichi Sankyo and Sarah Cannon Research Institute announced the dosing of the first patient in a first-in-human phase 1/2 study (NCT04145622) evaluating DS-7300.

What is DS-7300: DS-7300 is an investigational B7-H3 targeting antibody-drug conjugate (ADC).

What is B7-H3: It is a Type I transmembrane protein belonging to the B7 family, which includes immune checkpoint molecules such as CTLA-4 ligands, and PD-L1. The protein is more highly expressed in various solid cancers, compared to normal tissues. Overexpression of B7-H3 is associated with poor prognosis in some solid cancers including NSCLC and prostate cancer.

In what patient segment is the drug being evaluated: The drug is being developed for the treatment of patients with advanced solid malignant tumors.

Where is the trial being conducted: The trial is being conducted in the US and Japan.

How many patients are expected to be enrolled: A total of approximately 160 patients are expected to be enrolled in this study.

Read the complete story Daiichi Sankyo here.

How many ADCs are being developed for solid tumors: As per a recent report by Roots Analysis, currently, more than 240 ADCs are being developed across various clinical/preclinical stages. The majority of clinical ADCs are being developed for the treatment of patients with solid tumors.

Antibody Drug Conjugates Pipeline based on the analysis done by Roots

With such a strong development pipeline, the overall ADC therapeutics market is projected to be worth $15 billion by 2030, growing at a CAGR of over 20%. This fast-growing market offers immense opportunities for contract manufacturers, service providers, and technology developers.